c-LEcta has broadened the intellectual property position (IP) of its core technology platform with patent grant on its high throughput Cluster Screening method by the European Patent Office (EP 1678299 B1).
Cluster Screening forms an integral part of c-LEcta’s technology IP portfolio, further comprising library design, multi-parameter engineering & screening, and enzyme expression methodologies. In particular, Cluster Screening enables efficient selection of enzyme variants under use-oriented conditions in high throughput, e.g. in biodiversity and engineering screenings.
c-LEcta’s technology platform as well as bioprocess and enzyme manufacturing skills form the basis for its remarkable enzyme development success, proven in many industry partnerships, implemented biotechnology processes, and commercial products in various industries.
Cluster Screening forms an integral part of c-LEcta’s technology IP portfolio, further comprising library design, multi-parameter engineering & screening, and enzyme expression methodologies. In particular, Cluster Screening enables efficient selection of enzyme variants under use-oriented conditions in high throughput, e.g. in biodiversity and engineering screenings.
c-LEcta’s technology platform as well as bioprocess and enzyme manufacturing skills form the basis for its remarkable enzyme development success, proven in many industry partnerships, implemented biotechnology processes, and commercial products in various industries.
